Who are Viagra (sildenafil citrate)'s main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): ZYDENA TAB.75mg(Udenafil 75mg), LEVITRA (vardenafil).

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/viagra-sildenafil-citrate.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-16 · How we verify

Viagra (sildenafil citrate) — Competitive Intelligence Brief

Viagra (sildenafil citrate) (Viagra (sildenafil citrate)) competitive landscape: 2 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Phosphodiesterase type 5 (PDE5) inhibitor. Area: Urology / Cardiovascular.

marketed Phosphodiesterase type 5 (PDE5) inhibitor PDE5 (phosphodiesterase type 5) Urology / Cardiovascular Small molecule Live · refreshed every 30 min

Target snapshot

Viagra (sildenafil citrate) (Viagra (sildenafil citrate)) — Pfizer's Upjohn has merged with Mylan to form Viatris Inc.. Sildenafil inhibits phosphodiesterase type 5 (PDE5), allowing cyclic GMP to accumulate and promote smooth muscle relaxation in the corpus cavernosum, increasing blood flow to the penis.

Comparator set (2 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
Viagra (sildenafil citrate) TARGET	Viagra (sildenafil citrate)	Pfizer's Upjohn has merged with Mylan to form Viatris Inc.	marketed	Phosphodiesterase type 5 (PDE5) inhibitor	PDE5 (phosphodiesterase type 5)
ZYDENA TAB.75mg(Udenafil 75mg)	ZYDENA TAB.75mg(Udenafil 75mg)	Samsung Medical Center	marketed	Phosphodiesterase type 5 (PDE5) inhibitor	PDE5 (phosphodiesterase type 5)
LEVITRA (vardenafil)	LEVITRA (vardenafil)	GlaxoSmithKline	marketed	Phosphodiesterase type 5 (PDE5) inhibitor	PDE5 (phosphodiesterase type 5)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Phosphodiesterase type 5 (PDE5) inhibitor class)

GlaxoSmithKline · 1 drug in this class
Pfizer's Upjohn has merged with Mylan to form Viatris Inc. · 1 drug in this class
Samsung Medical Center · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Viagra (sildenafil citrate) — Competitive Intelligence Brief. https://druglandscape.com/ci/viagra-sildenafil-citrate. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab